Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutated NSCLC Presented at WCLC 2020Daiichi Sankyo2021-02-02 11:10:14New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutated NSCLC Presented
-
Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung CancerDaiichi Sankyo2021-02-02 11:32:38Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small
-
ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics SocietyDaiichi Sankyo2021-02-02 11:32:52ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society
-
ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-02-02 11:33:01ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer
-
New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung CancerDaiichi Sankyo2021-02-02 11:33:08New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung
-
TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC with Actionable Genomic AlterationsDaiichi Sankyo2020-12-14 15:35:37TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC
-
TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in Previously Treated Patients with Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsDaiichi Sankyo2020-12-14 15:36:13TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in
-
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast CancerDaiichi Sankyo2020-12-14 14:49:29Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast Cancer
-
Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2 Expressing Metastatic Breast Cancer Presented at the 2020 San Antonio Breast Cancer SymposiumDaiichi Sankyo2023-11-10 06:53:58Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2
-
ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive Metastatic Breast CancerDaiichi Sankyo2023-11-10 06:54:59ENHERTU® Continues to Demonstrate Durable Responses with New Data from DESTINY-Breast01 in HER2 Positive
